Archive for February 2016

Cholesterol Meds – Awesome or Awful?

Statins – those frequently-prescribed cholesterol-lowering medicines that include Zocor (simvastatin), Lipitor (atorvastatin), Crestor (rosuvastatin), Livalo (pitavastatin), Mevacor (lovastatin), Lescol (fluvastatin), and Pravachol (pravastatin) – are they awful toxins or awesome remedies?  You can certainly read both opinions if you follow the news or scan the web.  The New York Times once touted them as “the underused wonder drugs” while other articles and blogs claim they are dangerous and no one should use them.  Meanwhile they are the most prescribed drugs in the world and over 20 million Americans take them.

So where is the truth when it comes to statins?  No one can credibly claim that they don’t effectively lower cholesterol.  We routinely see up to and beyond 100 point drops three weeks into treatment with a statin.  What’s more, they act as anti-inflammatants inside the blood vessels and inflammation promotes plaque formation (the stuff that damages and blocks arteries leading to heart attacks and strokes).  But does lowering cholesterol and inflammation translate into reduced heart attacks, strokes, and overall mortality?  For high-risk individuals who have already had a coronary event (a heart attack or stent or bypass surgery) the answer is clearly, yes.  Statins reduce the chance of a second heart attack by about a third.

However, in what’s called primary prevention – preventing bad outcomes in individuals who are at lower risk and have never had a coronary event – the numbers are still there, but not quite as compelling.  An analysis of 14 randomized trials involving almost 35 thousand patients showed the following:

  • 17% reduction in all-cause mortality
  • 28% reduction in heart attacks
  • 22% reduction in strokes
  • No significant additional adverse events in those treated vs. placebo groups nor negative effect on quality of life

That sounds fairly impressive, but put another way, when the numbers are worked out, 1000 people would have to be treated for one year to prevent one death.  So there is a real, but modest benefit in treating lower risk individuals with statins.

On the side-effect side of the equation, we already noted that substantial side effects seem to be statistically insignificant in the studies.  But that’s not the whole story.  Liver effects are actually rather uncommon, with a significant rise in liver enzymes occurring in roughly 1 in 100 patients.  If they occur, the statin is simply stopped and the enzymes return to normal.  Actual liver failure rates in those on statins are almost the same as those in the untreated population.

Muscle pains occur in some 10% (estimates vary) of those on statins and, again, generally resolve promptly when the statin is stopped.  More serious muscle damage can occur, though rarely (in over 25 years of prescribing I’ve not had my first yet).  Other recent findings note a slight rise in blood sugar with statins and a fairly uncommon incidence of mental fuzziness and memory issues. If the latter occurs, the statin can be stopped and the problem clears.  All in all, my experience has been that some 8 out of 10 persons put on statins have no problem.

So, in the real world, if you have high cholesterol, how do you decide whether to be on a statin?  Sit down with your physician and go over your cholesterol numbers in detail.  Then look at all your other risk factors for heart disease and stroke (smoking, hypertension, diabetes, family history, sedentary life style, etc.).  For many I also recommend a coronary calcium score (a rapid, non-invasive CT of the coronary arteries looking for calcified plaque), a cardiovascular inflammation panel (I use Cleveland Heart Lab), and sometimes a CIMT (carotid intima media thickness, an evaluation of the state of plaque formation and inflammation in the blood vessels).  These tools give us a much better handle on who really is showing blood vessel damage and risk and who isn’t.  This allows us to target our preventive efforts, including statin use, on those who will most benefit from it.  Of course in all of this, don’t forget lifestyle changes such as the one highlighted in another New York Times article: “Underused Therapy for the Heart: the Gym.”

So statins are neither simply awesome nor awful; they’re one treatment that may or may not be right for you, when added to your steady efforts to minimize all those other risk factors.

More

Direct Primary Care legislative promo video

Recently I had a the opportunity to be interviewed by the Beacon Center of Tennessee for promotional video on Direct Primary Care to help support the pending Tennessee legislation on the matter. 

You can watch the video at the link below. 

Consider contacting your local representative to help support this bill and provide DPC the full opportunity to help our community that has been so impacted from rising health insurance premiums. When people spend a forture on health insurance they are often shocked that they still have to buy health care. DPC allows me to lower the cost of health care regardless of insurance coverage.

Direct Primary Care Promo Video

More

A soured system can be renewed into sweet success

Patrick Rohal, MD opened his Direct Primary Care program the same day I did.  He offers some rewarding insights from the first month of practice that are worth reading.  He shows us that we can really take our current national healthcare system that is slowing souring and revitalize it back to the sweet, relational, successful community oriented program it had been for hundreds of years.  Join me in retaking primary care to be about the patient and driven by the patient needs.  More information is here and you can sign up for our program here.

Reflections on My First Month as a Direct Primary Care Doctor

http://www.covenantmd.net/blog/2016/2/1/reflections-on-my-first-month-as-a-direct-primary-care-doctor

More